Broncus Completes $200 Million Hong Kong IPO for Pulmonary Devices

Broncus Holding, a Hangzhou pulmonary medical device company, completed a $200 million IPO on the Hong Kong exchange that valued the company at nearly $1.3 billion. Its products, which are marketed in China and globally, address navigation, diagnosis and treatment needs for lung cancer, COPD and emphysema. The IPO was priced at the top end of the range, but on its first day of trading, Broncus' shares dropped 20%. Founded in 2012, Broncus posted net losses of $32.6 million in 2019 and $48.8 million in 2020, with revenue falling 59% in 2020. More details.... Stock Symbol: (HK: 2216) Share this with colleagues: // //
Data & News supplied by
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.